Clinical Trial Update: A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of cisplatin plus pemetrexed and bevacizumab as first-line therapy for non-small cell lung cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Avastin (bevacizumab)
• Platinol (cisplatin)

Snippet

Sponsor: Columbia University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-07-30